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Abstract
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HIV-positive women are infected with human papillomavirus (HPV) (especially with multiple
types), and develop cervical intraepithelial neoplasia (CIN) and cervical cancer more frequently
than HIV-negative women. We compared HPV DNA prevalence obtained using a GP5+/6+ PCR
assay in cervical exfoliated cells to that in biopsies of 468 HIV-positive women from Nairobi,
Kenya. HPV prevalence was higher in cells than biopsies and the difference was greatest in 94
women with a combination normal cytology/normal biopsy (prevalence ratio, PR=3.7; 95%
confidence interval, CI: 2.4–5.7). PR diminished with the increase in lesion severity (PR in 58
women with high-grade squamous intraepithelial lesions (HSIL)/CIN2-3 =1.1; 95% CI: 1.0–1.2).
When HPV-positive, cells contained 2.0-to-4.6 fold more multiple infections than biopsies.
Complete or partial agreement between cells and biopsies in the detection of individual HPV types
was found in 91% of double HPV-positive pairs. The attribution of CIN2/3 to HPV16 and/or 18
would decrease from 37.6%, when the presence of these types in either cells or biopsies was
counted, to 20.2% when it was based on the presence of HPV16 and/or 18 (and no other types) in
biopsies. In conclusion, testing HPV on biopsies instead of cells results in decreased detection but
not elimination of multiple infections in HIV-positive women. The proportion of CIN2/3
attributable to HPV16 and/or 18 among HIV-positive women, which already appeared to be lower
than that in HIV-negative, would then further decrease. The meaning of HPV detection in cells
and random biopsy from HIV-positive women with no cervical abnormalities remains unclear.
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Assignment of human papillomavirus (HPV) type to individual cervical lesions is essential
to understand the biology of different HPV types; the efficacy of HPV vaccines, and which
types should be included in HPV detection assays1,2 In particular, high-risk (hr) HPV
infection is detected in the vast majority of high-grade cervical intraepithelial neoplasia
(CIN) 2 and 3, and HPV16 and 18 are implicated in over half of HPV-positive CIN2/3.1
Genital multiple-type infections are however frequent in women with and without
precancerous and cancerous lesions1,2, notably in HIV-positive women who are at increased
risk to acquire HPV infection, develop a persistent HPV infection, and progress to CIN2/3
or invasive cervical carcinoma (ICC).3,4
Comparison of cytological and histological samples can help to distinguish the broad range
of HPV types, including low-risk types, that are present in exfoliated cervico-vaginal cells
from the fewer that are detected in cervical tissue biopsies and are likelier to include the
causal type.5 Colposcopy-guided biopsies can detect the presence of HPV types in the
worst-looking area of the cervix6 but random biopsies can also identify lesions and HPV
infections in an apparently normal cervix.7
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Here we describe the detection of different HPV types in paired samples of cervical
exfoliated cells and formalin-fixed paraffin-embedded tissue biopsies that were collected at
the same study visit in HIV-positive women who participated in a cervical cancer screening
study in Nairobi, Kenya. Our aims are to compare: 1) the prevalence and agreement in HPV
type and multiple infections between cervical exfoliated cells and biopsies, and 2) the
influence of reliance on either or both two types of samples on the assignment of a CIN2/3
lesion to HPV16 and/or 18.

MATERIALS AND METHODS
Participants and study procedures
HIV-positive women who attended the Coptic Hope Center for Infectious Diseases, Nairobi,
Kenya in 2009 to receive HIV-related care were invited to participate in a study on cervical
cancer screening methods. They were eligible if they were: between 18 and 55 years of age;
not screened in the last year; and never treated for cervical cancer or pre-cancerous
lesions.8–10 In total, 498 women were included.
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After obtaining a written informed consent, information on clinical and lifestyle
characteristics of study women was collected. A medical examination was performed and
biological specimens were taken. Briefly, cervical exfoliated cells (hereafter for brevity
referred to as cells) were collected by a nurse using a Cervex-Brush (Rovers Medical
Devices, Oss, the Netherlands) and smeared on a glass slide for conventional cytological
examination. The brush was then placed in PreservCyt medium (Hologic, Marlborough,
MA, USA) for HPV testing. A medical doctor performed a colposcopic examination and
took a biopsy from all women, either from the colposcopically worst-looking area on the
cervix or, if no lesion was visualized, at 12 o’clock (i.e., the most frequent location of
cervical lesions). Biopsy tissues were immediately immersed in 10% buffered formalin and
transported to the pathology laboratory the same day.
The study protocol was approved by the Ethical Review Committees of the Kenyatta
National Hospital, Kenya; the University of Washington, USA; and the International
Agency for Research on Cancer, France.
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Cytology and histology
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Cytological slides and biopsies were processed by staff under the supervision of the study
pathologist (Dr. Farzana Rana) at the Aga Khan University, Nairobi, who also read all the
cytological and histological slides. Cytological slides were processed within a week and
reported according to the Bethesda 1991 revised classification.11 Formalin removal and
paraffin embedding of the biopsies were performed with strict adherence to the appropriate
procedures within 24 hours after arrival in the laboratory.12 The formalin-fixed and paraffinembedded tissue blocks that remained after the preparation of histology slides were stored
and sent to the Department of Pathology of the Vrije University Medical Centre,
Amsterdam, The Netherlands, where new tissue cuts were made for HPV DNA testing and
for a separate histological assessment. Fourteen blocks were missing, and hence these cases
were excluded. The Amsterdam histological assessment was used for this report, except for
13 ‘indeterminate’ results, of which 11 had a valid histological diagnosis on local biopsy
slides (three normal results, five CIN1 and three CIN2). Two cases that were ‘indeterminate’
on both local assessment and in Amsterdam were excluded.
HPV DNA testing
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HPV DNA testing was performed on cervical exfoliated cells and tissue biopsies at the
Department of Pathology at the Vrije University Medical Center, Amsterdam, The
Netherlands. DNA was extracted from the PreservCyt specimen using magnetic beads
(Macherey-Nagel, Dueren, Germany) on a robotic system (Hamilton, Germany), according
to the manufacturer’s instructions. Biopsies were sectioned using a ‘sandwich’ approach,
whereby inner sections were destined for HPV testing and outer sections for histological
examination. One or more 5-μM sections representing approximately one cm2 of tissue
were predigested with proteinase K after which DNA was extracted. Beta-globin PCR
analysis was performed in order to assess the DNA quality. The presence of HPV DNA was
first determined using general primer GP5+/6+-mediated PCR.13 PCR products were
hybridized using an enzyme immunoassay (EIA) that included two oligoprobes: one for
hrHPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 and another for lowrisk HPV types 6, 11, 26, 30, 32, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 64, 67, 69, 70, 71, 72,
73, 81, 82/mm4, 82/is39, 83, 84, 85, 86, 89 and 90. Subsequent HPV typing was performed
by reverse-line blot hybridisation of PCR products, as described previously.14 HPV types of
IARC classification group 1 “carcinogenic to humans” (HPV16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58 and 59) and group 2A “probably carcinogenic to humans” (HPV68) were
considered as high-risk types.15 All other HPV types were considered low-risk types.
Specimens that were positive at EIA, but did not reveal any known genotype, were classified
as uncharacterized types. No cells specimens were beta-globin negative. Twenty-four
biopsies were beta-globin negative but positive for HPV testing and were kept in the current
analysis. Conversely, 12 biopsies that were negative on both tests were excluded from this
report.
Statistical analysis
The prevalence of HPV infection (any type; hrHPV types; and multiple types) in cells was
compared with the prevalence in biopsies from the same woman using prevalence ratios
(PRs) and corresponding 95% confidence intervals (CIs) of HPV. In order to account for the
individual matching of the two samples, we used a generalized estimating equations (GEE)
model for binary outcome with a log link (as opposed to the routine logistic model) and an
exchangeable correlation structure. In order to take into account the strengths and
weaknesses of different types of samples (i.e., the greater reliability of histological diagnosis
but also severe dependence on sampling area), PRs were stratified by cervical status defined
as a composite cytological and histological classification of study women into: a) normal
findings in both cells and biopsy; b) any finding in cells and CIN1 in biopsy (or atypical
Int J Cancer. Author manuscript; available in PMC 2014 September 15.
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squamous cells of undetermined significance or worse with normal biopsy, n=98); c) cells
<HSIL and biopsy CIN2/3; and d) cells HSIL and biopsy CIN2/3. Two cases were excluded
due to undetermined cytology combined with CIN2/3 histology.
Agreement in the detection of individual HPV types in paired HPV-positive samples was
classified as “complete” if all types detected in the two samples were the same, or “partial”
if extra types were found in cells or biopsy. “Discordant” pairs were those in which cells and
biopsy included no overlapping types. Finally, five possible strategies were used to establish
the proportion of CIN2/3 attributable to HPV16 and/or 18. Assignment to HPV types was
alternatively based on: a) cells; b) biopsy; c) biopsy or, in case of a HPV-negative biopsy,
cells; d) either cells or biopsy regardless of whether any of the two was negative; and e)
positivity for HPV16 and/or 18 infection in biopsy in the absence of other types.

RESULTS
The mean age of 468 women included in this report was 38.2 years (5%-95% percentiles:
27–51). Cervical biopsy was normal in 204 women (43.6%), CIN1 in 155 women (33.1%);
CIN2 in 49 (10.5%); and CIN3 in 60 (12.8%). No ICCs were found.
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Table 1 shows a comparison of the prevalence of HPV (any type; hrHPV types; and multiple
types) in cervical exfoliated cells and biopsies by cervical status. HPV prevalence steadily
increased from normal cytology/normal biopsy to HSIL/CIN2-3 women in both cells and
biopsies. The difference in HPV prevalence between cells and biopsies was greatest in
normal/normal women (PR = 3.7; 95% CI: 2.4–5.7) and any/≤CIN1 (PR = 2.3; 95% CI: 1.9–
2.7). The similarity in HPV prevalence in cells and biopsies increased with the severity of
cytological and histological findings, PR in cells versus biopsies was 1.4 (95% CI: 1.1–1.7)
among <HSIL/CIN2-3 women and 1.1 (95% CI: 1.0–1.2) among HSIL/CIN2-3 women.
Similar results were found when analyses were restricted to hrHPV (Table 1). HPV-positive
cells contained 2.0-to-4.6 fold more multiple infections than HPV-positive biopsies
depending on cervical status and the smallest difference was found among HSIL/CIN2-3
women (PR = 2.0; 95% CI: 1.4–2.9). Findings were similar in separate strata by CD4 count
and combination antiretroviral therapy use (data not shown).
Table 2 shows the agreement for the presence of any HPV type in cells and biopsies by
cervical status and overall. Overall agreement was 65.2% but it increased from 52.1% in
normal/normal to 89.7% in HSIL/CIN2-3 women. The percent of double HPV-positivity
increased from 16.0% in normal/normal women to 87.9% in HSIL/CIN2-3 women. The vast
majority of discordant pairs contained HPV in cells only (n=157), whereas HPV in biopsy
only was found in ≤2% in all cervical status strata.
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HPV type-specific agreement was evaluated in 161 pairs in which both cells and biopsy
were HPV-positive (Table 3). Complete agreement of HPV type detection was found in 55
pairs (34.2%). In 46.6% of pairs partial agreement with extra types in cells was found. In
8.7% of women there was a complete discordance in HPV type detection.
Table 4 shows the number and percentage of CIN2/3 attributable to HPV16 and/or 18
according to different strategies in descending order. Percentage was 37.6% based on the
presence of HPV16 and/or 18 in either cells or biopsy. It slightly declined when only cells
(35.8%) or biopsy and cells (in case of HPV-negative biopsy) (32.1%) were used. Relying
only on the presence of HPV16 and/or 18 in biopsies or exclusively on biopsies in which no
types other than HPV16 and 18 were detected led to fractions of 27.5% and 20.2%,
respectively (Table 4).
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Our study is the first to compare systematically the detection of HPV infection in paired
samples of cervical exfoliated cells and biopsies in HIV-positive women. As expected,4 the
prevalence of HPV infection and cervical precancerous lesions among HIV-positive women
was high. HPV prevalence was significantly higher in cells, compared to biopsies among
women without CIN2/3 but similar among women with CIN2/3. Multiple infections were 2to-5-fold more often detected in cells than biopsies. The smallest difference between the two
samples, but also the highest prevalence of multiple infections in biopsies was found among
women in whom high-grade lesions were detected in both cells and biopsy. Complete or
partial agreement in the detection of individual HPV types was found in the majority of
double HPV-positive pairs, with little variation by cervical status. Attribution of CIN2/3 to
HPV16 and/or 18 ranged between 20.2% and 37.6% depending on the way HPV findings
from cells and biopsies were used separately or in combination.
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More frequent detection of HPV infection and multiple HPV types in cells than in biopsies
is not surprising as exfoliated cells can come from a wide genital area including the whole
cervix, vagina and vulvar opening whereas biopsies are restricted to a small portion of the
cervix, i.e., the area supposed to contain the relevant lesion. The presence of CIN2/3 in a
biopsy greatly diminished differences in HPV findings between the two samples especially
if HSIL had been concurrently detected in cells. The especially strong disagreement in HPVpositivity and prevalence of multiple infections in women without CIN2/3 may be explained
by a high proportion of transient rather than persistent infections in CIN1 lesions.5 In
addition, colposcopical identification of “the worst” cervical area is sometimes inaccurate
and a single random biopsy in the absence of visible lesions is especially likely to miss
HPV-infected areas.
HPV infection was detected in biopsies from 16 women (17%) in whom no abnormalities
were found in either cells or biopsy. Among them, only one woman harboured HPV
infection in random biopsy but not in cells. It is unclear whether the presence of HPV
infection in normal cervical tissue is increased in HIV infection as similar data on HIVnegative women without cervical abnormalities are very limited. De Sanjose et al.16
compared HPV findings obtained using GP5+/GP6+ in cells and frozen biopsies in 99 HIVnegative middle-age women with a normal cervix, but the majority of women (80%) were
HPV-negative.16 One cell-negative woman was HPV-positive at biopsy while two biopsynegative women were HPV-positive in cells.
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Other studies reporting on the agreement in HPV detection in cells and biopsies in HIVnegative women were restricted to women with cervical abnormalities.5,17,18 In agreement
with our study, multiple infections were always detected more frequently in cells than in
biopsies. However, the studies used HPV assays with different sensitivity compared to the
test we used, and, in some instances, used different HPV assays for cells and biopsies,5,17
which had an impact on the comparison between cells and biopsies in those studies. Quint et
al.18 compared HPV-prevalence in exfoliated cells and formalin-fixed biopsies from 174
women with CIN1-3 using ultra-sensitive SPF10 PCR. They found no significant
differences in HPV prevalence in exfoliated cells and biopsies (92% vs. 94%, respectively)
and a similar distribution of individual HPV types. Gravitt et al.17 compared paired
exfoliated cells obtained with cervico-vaginal lavage and formalin-fixed biopsies from 146
women with CIN1-3. MY09/11 and SPF10 PCR assays were used, respectively, on cells and
biopsies. They reported a slightly higher HPV prevalence by cells than biopsies (99.3% vs.
92.5%, respectively). The prevalence of HPV16 and/or 18, however, was similar.17

Int J Cancer. Author manuscript; available in PMC 2014 September 15.
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Laser capture micro-dissection (LCM) with high resolution genotyping is the most accurate
technique for assigning HPV type to an area of CIN.5,19 When multiple HPV types were
present in the whole-tissue section, association of a single type with a discrete area of CIN
was found for 93% (372/399) of LCM fragments analysed with SPF10 PCR/LiPA25.19
However, rarely detected colliding CIN lesions can be associated with multiple HPV types.
In another study LCM was applied to 13 women with high-grade lesions and genotyping
was repeated, in each woman, on cytology and four different areas of the cervix.5 Four
women had multiple HPV types in their biopsies but only one had two different types in
morphologically distinct but colliding lesions on LCM. Interestingly, HPV16 was identified
as the causal type in all women with HPV16 in cytology.5
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Major strengths of our study include the large number of women whose diagnosis ranged
from normal cervix to CIN3 and availability for all women of a biopsy taken at the same
time of cells collection. A PCR assay more sensitive than GP5+/GP6+ and more robust to
DNA degradation in formalin-fixed paraffin-embedded tissue blocks (e.g., SPF10),5,17,18
would have detected more infections and multiple infections in biopsies. The use in our
study of a strict protocol for tissue biopsy preparation and the exclusion of beta-globin
negative/HPV negative biopsies should have improved, however, the quality of biopsy
findings. Although we found a substantial agreement for the presence of at least one
common HPV type in HPV-positive pairs of cells and biopsies (93.8%) among women with
CIN2/3, conclusions about the attribution of CIN2/3 to HPV16 and/or 18 were influenced by
different reliance on results from cells and biopsies. Attribution to HPV16 and/or 18 ranged
from 20.2% when it was based on the detection of HPV16 and/or 18 in biopsies in the
absence of any other type to 37.6% when detection in either cells or biopsy was taken into
account. Of note, our upper threshold is somewhat lower than the pooled prevalence of
HPV16 and 18 in a meta-analysis of HIV-positive women with HSIL or CIN2/3 (31.9% and
12.9%, respectively), but no information on whether both types were present.4 Our upper
threshold is, however, similar to the proportion of cervical high-grade lesions (HSIL and/or
CIN2/3) associated with HPV16 and/or 18 in African studies that excluded women known to
be HIV-positive (36.9%, the lowest among all world regions).1
In conclusion, our present study shows that testing HPV on biopsies instead of cells results
in decreased detection but not elimination of multiple infections in HIV-positive women.
Relying exclusively on biopsies decreases the proportion of CIN2/3 presumably attributable
to HPV16 and/or 18 among HIV-positive women, but accurate assignment of HPV type
would require a LCM-based study. The meaning of HPV detection in cells and random
biopsy from HIV-positive women with no evidence of cervical lesions is also, for the
moment, unclear.
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CIN

cervical intraepithelial lesion

EIA

enzyme immunoassay

GEE

generalized estimating equations

HPV

human papillomavirus

hr

high-risk

HSIL

high-grade squamous intraepithelial lesion

ICC

invasive cervical carcinoma

PR

prevalence ratio
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Attribution of cervical lesions to an individual HPV type in HIV-positive women is
hampered by the high proportion of multiple infections. Our study is the first to compare
systematically HPV detection in paired cervical exfoliated cells and biopsies samples.
HPV testing on biopsies instead of cells diminished but did not eliminate the high
prevalence of multiple infections. Exclusive reliance on biopsies decreased the
proportion of CIN2/3 attributable to vaccine-preventable HPV16 and/or 18 in HIVpositive women.
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CIN2/3

HSIL

167 (63.0): 74 (27.9)
42 (82.4): 31 (60.8)
56 (96.6): 52 (89.7)
324 (69.2): 173 (37.0)

51
58
468

59 (62.8): 16 (17.0)

Cells: biopsy
N (%): N (%)

Any HPV

265

94

N

1.1 (1.0–1.2)

1.4 (1.1–1.7)

2.3 (1.9–2.7)

3.7 (2.4–5.7)

PR

hrHPV

246 (52.6): 133 (28.4)

52 (89.7): 47 (81.0)

37 (72.6): 26 (51.0)

120 (45.3): 49 (18.5)

37 (39.4): 11 (11.7)

Cells: biopsy
N (%): N (%)

1.1 (1.0–1.2)

1.4 (1.1–1.8)

2.5 (2.0–3.1)

3.4 (2.0–5.6)

PR

CIN: cervical intraepithelial neoplasia; hr: high-risk; HSIL: high-grade squamous intraepithelial lesion.

Including normal biopsies only in combination with any cytological abnormality.

a

CIN2/3

<HSIL

Overall

≤CIN1a

Norm

Norm

Any

Histo

Cyto

Cervical status

189 (58.3): 41 (23.7)

39 (69.6): 18 (34.6)

28 (66.7): 5 (16.1)

92 (55.1): 16 (21.6)

30 (50.8): 2 (12.5)

Cells: biopsy
N (%): N (%)

PR

2.0 (1.4–2.9)

4.6 (2.0–10.6)

2.7 (1.7–4.2)

3.9 (1.1–14.4)

Multiple types

Prevalence ratio (PR) of human papillomavirus (HPV) infection (any, high-risk and multiple types) in cervical exfoliated cells versus biopsies by cervical
status. Kenya 2009
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51 (87.9)
167 (35.7)

58
468

CIN2/3

HSIL
157 (33.5)

5 (8.6)

12 (23.5)

96 (36.2)

44 (46.8)

Cells+/biopsy- N (%)

CIN: cervical intraepithelial neoplasia; HSIL: high-grade squamous intraepithelial lesion.

6 (1.3)

1 (1.7)

1 (2.0)

3 (1.1)

1 (1.1)

Cells-/biopsy+ N (%)

Any HPV

Including normal biopsies only in combination with any cytological abnormality.

a

30 (58.8)

51

CIN2/3

<HSIL

Overall

71 (26.8)

≤CIN1a

Any

15 (16.0)

94
265

Norm

Norm

Cells+/biopsy+ N (%)

Histo

N

Cyto

Cervical status

138 (29.5)

1 (1.7)

8 (15.7)

95 (35.8)

34 (36.2)

Cells-/biopsy- N (%)

65.2

89.7

74.5

62.6

52.1

Agreement (%)

Agreement in human papillomavirus (HPV) positivity (any type) between paired cervical exfoliated cells specimens and biopsies by cervical status.Kenya
2009
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19 (38.0)
55 (34.2)

50
161c

CIN2/3

HSIL

Including normal biopsies only in combination with any cytological abnormality.

CIN: cervical intraepithelial neoplasia; HSIL: high-grade squamous intraepithelial lesion.

6 women with uncharacterized HPV types are not included.

c

b

75 (46.6)

25 (50.0)

13 (43.3)

31 (46.3)

6 (42.9)

Partial agreement (extra types in
cells)
N (%)

Only pairs in which both cells and biopsy were HPV-positive.

a

11 (36.7)

30

CIN2/3

<HSIL

Overall

21 (31.3)

67

≤CIN1b

Any

4 (28.6)

14

Norm

Norm

Complete agreement
N (%)

Histo

N

Cyto

Cervical status

6 (3.7)

2 (4.0)

1 (3.3)

2 (3.0)

1 (7.1)

Partial agreement (extra types in
biopsy)
N (%)

HPV, individual types

11 (6.8)

2 (4.0)

2 (6.7)

7 (10.4)

0 (0.0)

Partial agreement (extra types in
both)
N (%)

14 (8.7)

2 (4.0)

3 (10.0)

6 (9.0)

3 (21.4)

All discordant
N (%)

Agreement in detection of individual human papillomavirus (HPV) types between cervical exfoliated cells and biopsiesa, by cervical status. Kenya 2009
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Number and percentage of CIN2/3 (N=109) attributable to HPV16 and 18 according to different strategies.
Kenya 2009.
Strategy

CIN2/3 attributable to HPV16/18
No
n (%)

Yes
n (%)

Cells or biopsy

68 (62.4)

41 (37.6)

Cells only

70 (64.2)

39 (35.8)

Biopsy or, if biopsy was HPV-negative, cells

74 (67.9)

35 (32.1)

Biopsy only

79 (72.5)

30 (27.5)

Biopsy, no types other than HPV16/18

87 (79.8)

22 (20.2)

CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus.
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